U.S. FDA allows importing of 2 million baby formula cans from UK
Send a link to a friend
[May 25, 2022] By
Ahmed Aboulenein and Ananya Mariam Rajesh
WASHINGTON (Reuters) -The U.S. Food and
Drug Administration is easing regulations to allow infant formula
imports from Britain, a move it said on Tuesday would bring around 2
million cans onto empty shelves by June to ease a nationwide shortage.
The FDA said it was "exercising enforcement discretion" to allow
Britain-based Kendal Nutricare to import certain infant formula products
under the Kendamil brand that it has no safety or nutrition concerns
over following an evaluation.
"Under the agency's recent increased flexibilities regarding importation
of certain infant formula products, the company initially estimates that
about 2 million cans of infant formula are expected to land on U.S.
store shelves beginning in June," it said in a statement.
Kendal has 40,000 cans in stock for immediate dispatch that the
Department of Health and Human Services is working on bringing into the
United States as soon as possible, the FDA said.
"We continue to do everything in our power as part of the
all-of-government efforts to ensure there's adequate infant formula
available wherever and whenever parents and caregivers need it," said
FDA Commissioner Robert Califf.
The United States is experiencing one of the biggest infant formula
shortages in recent history after Abbott Laboratories in February
recalled some products including Similac and closed its manufacturing
plant in Sturgis, Michigan.
Abbott, the biggest U.S. supplier of powder baby formula, shut its
facility after reports of bacterial infections among four infants. It
exacerbated a shortage among multiple manufacturers that began with
supply-chain issues tied to the coronavirus pandemic.
[to top of second column]
|
Signage is seen outside of the Food and Drug Administration (FDA)
headquarters in White Oak, Maryland, U.S., August 29, 2020.
REUTERS/Andrew Kelly
The FDA said it would allow the release of about
300,000 cans of Abbott's EleCare amino acid-based formula for
children who urgently need it to survive, on a case-by-case basis.
EleCare was previously produced at the Sturgis facility but were not
part of the recall, the FDA said.
Abbott plans to restart production at the facility on June 4, it
said in a statement, adding it would prioritize making EleCare and
supplying it on or about June 20. Abbott said it would provide the
formula to children in need for free.
U.S. President Joe Biden's administration has sought to relieve the
shortage by importing emergency supplies from Europe, the first of
which arrived earlier this week. Biden invoked the Cold War-era
Defense Production Act to help boost supplies.
The FDA said on Tuesday it was in discussion with other
manufacturers over additional supplies and that it would prioritize
products that demonstrate safety, nutritional adequacy, and are
available in large quantities.
(Reporting by Ahmed Aboulenein in Washington and Ananya Mariam
Rajesh in Bengaluru; Additional reporting by Amruta Khandekar in
Bengaluru; Editing by Arun Koyyur and Richard Chang)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|